Uterine corpus myxoid leiomyosarcoma

Summary

Uterine corpus myxoid leiomyosarcoma (MONDO:0003928) is a disease. A subtype of myxoid leiomyosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	uterine corpus myxoid leiomyosarcoma
Mondo ID	MONDO:0003928
DOID	DOID:6567
NCIT	C40175
UMLS	C1519861
MedGen	311426
GARD	0023741
Anatomy (UBERON)	UBERON:0009853
Is cancer (heuristic)	no

Also known as: body of uterus myxoid leiomyosarcoma · myxoid leiomyosarcoma of body of uterus · uterine corpus myxoid leiomyosarcoma · uterine myxoid leiomyosarcoma

Disease family

This is a subtype of myxoid leiomyosarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system cancer › muscle cancer › smooth muscle cancer › leiomyosarcoma › myxoid leiomyosarcoma › uterine corpus myxoid leiomyosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.